Actively Recruiting
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
Led by Shu Wang · Updated on 2024-11-20
2806
Participants Needed
1
Research Sites
678 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Human epidermal growth factor receptor 2 (HER2) positive breast cancer is a molecular subtype with high malignancy and high risk to recurrence and metastasis. After the appearance of anti-HER2 targeted drugs, the prognosis and survival of these patients were greatly improved. In addition to trastuzumab and pertuzumab, the use of tyrosine kinase inhibitor (TKI) can further improve the survival. The evidence of previous adjuvant TKI anti-HER2 therapy was mainly from ExteNET study. However, due to the limitations of the times, ExteNET research is based on the background of only trastuzumab targeted therapy. Nowadays, there is no evidence that trastuzumab combined patuzumab,use of T-DM1, followed by sequential neratinib can still obtain absolute benefits. Therefore, there is no standard for the use of neratinib in current clinical practice. Investigators want to explore, in the real world, the efficacy and safety of sequential use of naratinib in adjuvant therapy.
CONDITIONS
Official Title
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with HER2 positive breast cancer diagnosed by core needle biopsy or operation at Peking University People's Hospital
- Treated at Peking University People's Hospital and underwent radical resection with hospitalization records
- Received standard anti-HER2 neoadjuvant or adjuvant therapy (trastuzumab, trastuzumab combined with pertuzumab, T-DM1)
- Signed and agreed to participate in the PKUPH breast disease cohort study
You will not qualify if you...
- Lack of clinical and pathological data such as imaging and pathological results
- Patients with metastatic breast cancer or bilateral breast cancer
- Failure to perform radical surgery
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peking University People's Hospital
Beijing, Beijing Municipality, China, 100044
Actively Recruiting
Research Team
Y
yuan peng, doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here